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Prader-Willi syndrome (PWS) is caused by a loss of paternally-
expressed genes in an imprinted region of 15q11.2-q13; the syndrome
affects 1 in 25,000 live births (Smith et al., 2003; Angulo et al., 2015).
Most instances of PWS (70%) are due to a “large” 4–5 Mb deletion in
15q11.2-q13 (Fig. 1A). All large PWS deletions include six imprinted,
protein-encoding genes (MKRN3, MAGEL2, NECDIN, C15ORF2, SNURF,
SNRPN), seven non-protein coding snoRNA genes (SNORD107,
SNORD64, SNORD108, SNORD109A, SNORD116, SNORD115, and
SNORD109B), and the long non-coding RNA, IPW (Cassidy and Driscoll,
2009). About 25% of instances of PWS are due to uniparental maternal
disomy, while b5% of cases result from unbalanced paternal transloca-
tions, imprinting defects, or microdeletions (Angulo et al., 2015;
Cassidy and Driscoll, 2009). The clinical phenotypes of PWS include hy-
perphagic obesity, hypogonadism, low growth hormone (GH) associat-
ed with short stature, hyperghrelinemia, and relative hypoinsulinemia
(Smith et al., 2003; Angulo et al., 2015; Butler et al., 2006). Although
over a dozenmousemodels of PWS have been generated, none develop
the hallmark obesity associated with PWS. Patient-speciﬁc iPSCs could
provide a novel model system with which to study the molecular etiol-
ogy of the disease.Results and discussion
Generation of iPS cell lines from PWS patients and conﬁrmation of geno-
types and pluripotency
We generated induced pluripotent stem cells (iPSCs) from three
large deletion (LD) PWS patients and onemicrodeletion (MD) PWS pa-
tient with the smallest deletion (118 kb deletion, Chr 15q:
15:25,257,217–15:25,375,376) identiﬁed to date (Table 1) (Bieth et
al., 2015). All iPSC expressed pluripotency markers at the protein and
transcript level, and differentiated to teratomas consisting of all three
germ layers (Supplemental Figs. 1–3).Methylation-speciﬁcmultiplex li-
gation probe ampliﬁcation assay (MS-MLPA) and comparative genome
hybridization single nucleotide polymorphism (CGH SNP) arrays con-
ﬁrmed the genotypes of the cell lines utilized in the study (Supplemen-
tal Figs. 4 and 5). G-banded karyotyping conﬁrms the absence of
balanced translocations for all lines (Supplemental Fig. 6). The 4–5 Mb
“large” deletions and the 118 kb microdeletion in the PWS patient
lines are below the level of resolution for G-banded karyotyping.
Microdeletion breakpoints were conﬁrmed with the Agilent High Den-
sity SNP array to encompass only three genes, all of which are non-cod-
ing RNA genes: SNORD109A, SNORD116, and IPW (Supplemental Fig. 5).
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Fig. 1. PWS iPSCs retain themolecular signature of PWS. A) The PWS locus contains non-imprinted genes (green), maternally imprinted, paternally expressed genes (blue), and paternally
imprinted, maternally expressed genes (pink). There are protein- coding (ovals) and non-protein coding RNA genes (squares and triangles) in the interval. Large deletions (LD) are bound
by breakpoints 1 or 2 and breakpoint 3. Patients harboringmicrodeletions (MD) deﬁne a minimum critical deletion region highlighted in orange containing three non-coding, paternally
expressedRNA genes. B, C)DNAmethylation at the PWS locus persists after reprogramming to iPSCand differentiation to neurons. GenomicDNA fromunaffected control (CON)peripheral
white blood cells, iPSC's, and iPSC-derived neurons havemethylation levels ranging from 0.38 to 0.58 indicating that one allele is methylated (methylation status is expressed as digested
sample relative to non-digested sample fraction). In PWS large deletion iPSCs, iPSC-derived neurons, and peripheralwhite blood cells, methylation levels of genomic DNA range from 0.80
to 1.05 indicating that all gDNA screened wasmethylated at both theNDN and SNRPN loci. There were no differences inmethylation levels of PWS large deletion, parthenogenic ESCs, and
ESC-derived neurons. Parthenogenic ESC and ESC-derived neurons were used as a positive control as all genetic content is maternally derived. There were also no differences in
methylation levels at NDN and SNRPN loci among unaffected control, PWS microdeletion iPSC and iPSC-derived neurons because these two genes are not included in the microdeletion
interval. Furthermore, methylation differences between genotypes of reprogrammed or differentiated material were not different than those for gDNA from primary peripheral white
blood cells on which no reprogramming or differentiation procedures have been performed. D-H) Genes in the PWS locus remain silenced after iPSC generation. Expression ofMAGEL2
and SNRPN can be detected in iPSC from unaffected control and PWS microdeletion individuals. However, SNORD109, SNORD116, and IPW expression are undetectable in iPSC from
both PWS large deletion and PWS microdeletion patients. These transcripts are present in iPSC from unaffected control individuals. The CON PSC bars in A and B represent data
averaged from the following unaffected control cell lines: 1043-D3 iPSC P11, 1058-B7 iPSC P11, S1111B iPSC P10, 1043-B1 iPSC P12, 1058-6 iPSC P12, 056LBT iPSC P10, 1016 iPSC P15,
and NYSCF1 HUES P20 (14). The PWS MD iPSC bars in A and B represent data averaged from 066MDA iPSC P10 and 066MDC iPSC P10. The PWS LD iPSC bars in A and B represent data
averaged from 031MT iPSC P10, 129C iPSC P9, and 139P iPSC P12. The parthenote ESC bars in A and B represent data averaged from pES2 P10, swaps1 P7, and swaps2 p7. The CON
neurons bar represents data averaged from mature neurons between day 30 and 35 from iPSC lines 1043-D3, s1111B, 1058-6, 1043-B1, s1034-A3, 1058-B7, HUES46, and 1013ASV.
The PWS MD neurons bar represents data averaged from mature neurons between day 30 and 35 from iPSC lines 066MDA, 066MDC, and 066MDE. The PWS LD neurons bar
represents data averaged from mature neurons between day 30 and 35 of differentiation from iPSC lines 031MT, 129C, 129M, and 139P. The parthenote neurons bar represents data
averaged from mature neurons between day 30 and 35 of differentiation from parthenogenetic ESC lines swaps1 and pES2. The qRT-PCR data in panels D-H represents averages from
the following iPSC cell lines, all of which are between passage 10 and 11, CON: 1043-D3, 1058-B7, s1034-A3, 056LBT, 1058-6, s1111b, PWS MD: 066MDA, 066MDC, 066MDE, and PWS
LD: 031MC, 031MT, 129C, 139P. [PSC = pluripotent stem cells, iPSC = induced pluripotent stem cells, ESC = embryonic stem cells].
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Maternal DNA methylation patterns persisted after reprogramming
and neural differentiation (Fig. 1B–C). PWS microdeletion iPSCs and
iPSC-derived neurons had mean methylation levels (expressed asdigested sample peak height/non-digested sample peak height) at
NDN and SNRPN that were not different from unaffected controls, in-
cluding unaffected control gDNAs from peripheral blood lymphoblasts
that were not subjected to manipulations such as reprogramming or
neural differentiation (Noggle et al., 2011). NDN and SNRPN are not
Table 1
Anthropometric data from PWS patients and reprogramming methods.
Cell line Genotype Gender BMI at biopsy or maximum lifetime BMI Reprogramming method
031M PWS type 1 large deletion F 15.52⁎ Stemgent mRNA
129 PWS type 2 large deletion M 49.4 Retrovirus
139 PWS type 1 large deletion M 57.3 Retrovirus
066MD PWS microdeletion F 55.4 Stemgent mRNA
⁎ Patient was still in ‘failure to thrive’ clinical phase at time of biopsy; maximum lifetime BMI not available.
529L.C. Burnett et al. / Stem Cell Research 17 (2016) 526–530included in themicrodeletion interval (Fig. 1A). PWS large deletion iPSC
and iPSC-derived neurons displaymethylation levels atNDN and SNRPN
approximately twice those of unaffected control and PWS
microdeletion iPSC and iPSC-derived neurons (Fig. 1B–C). Parthenoge-
netic embryonic stem cells (ESC) and ESC-derived neurons were used
as positive controls as they only contain maternal genetic material
(Sagi et al., 2016). DNA methylation levels at the NDN and SNRPN loci
were similar in pluripotent stem cells (PSC) and PSC-derived neurons
from PWS large deletion patients and parthenogenetic ESCs. Further-
more, the level of DNA methylation at the NDN and SNRPN loci did not
differ between PWS large deletion peripheral blood and iPSC and
iPSC-derived neurons, indicating that the manipulations of somatic
cell reprogramming and neural differentiation did not cause de-methyl-
ation of genomic DNA at the PWS loci (Fig. 1B–C). Method of
pluripotency induction had no impact on the genomic DNAmethylation
level at NDN or SNRPN.
Quantitative RT-PCR for PWS region genes was performed in iPSC
(Fig. 1D–H) from unaffected controls, PWS large deletion patients, and
a PWSmicrodeletion patient. Induced pluripotent stem cells from unaf-
fected controls expressed all geneswithin the PWS interval (Fig. 1D–M).
Expression levels of MAGEL2 and SNRPN are similar in PWS
microdeletion and control iPSC (Fig. 1D, E, I, J), as MAGEL2 and SNRPN
are not included in the PWS microdeletion interval. However,
SNORD109, SNORD116, and IPW are deleted on the paternal chromo-
some in the PWS microdeletion patient and the expression of these
genes remained silenced in PWS iPSC. All of the PWS interval genes -
speciﬁcallyMAGEL2, SNRPN, SNORD109, SNORD116, and IPW - remained
silenced in PWS large deletion iPSCs (Fig. 1D–M).
In the aggregate, PWS iPSC and iPSC-derived neurons retain themo-
lecular signature of PWS; in support of our ﬁndings, Chamberlain, et al.
and Yang, et al., and Stelzer, et al. have also reprogrammed PWS ﬁbro-
blasts to pluripotent iPSCs that maintain maternal DNA methylation at
the PWS locus following reprogramming (Yang et al., 2010;
Chamberlain et al., 2010; Stelzer et al., 2014). PWS iPSC and iPSC-de-
rived neurons have appropriate deletion breakpoints and gene copy
numbers in PWS and non-PWS regions as indicated by MLPA and
CGH-SNP arrays (Supplemental Figs. 4, 5). PWS region maternal DNA
methylation signatures persist following somatic cell reprogramming
to iPSC and differentiation of iPSC to neurons (Fig. 1B, C). Additionally,
PWS iPSC display appropriate absence of PWS region gene expression
in both large deletion and microdeletion lines (Fig. 1D–M).
Materials and methods
Human subjects
All studies and consenting procedures were approved by the Institu-
tional Review Boards of the participating institutions.
Fibroblast reprogramming to iPSC and PSC culture methods
Primary human ﬁbroblasts from unaffected controls and PWS pa-
tients were reprogrammed to iPSC using retrovirus reprogramming,
sendai virus reprogramming or mRNA reprogramming (Fusaki et al.,
2009; Takahashi et al., 2007). The Stemgent mRNA reprogramming kit
(00-0071) plus miRNA mixture were used. 15 K to 30 K ﬁbroblastswere plated on gelatin-coated tissue culture 12-well dishes. Ideal densi-
ty was determined by eye. One-to-two days after seeding ﬁbroblasts,
the miRNA cocktail was added to the ﬁbroblasts (day 0 of
reprogramming). The mRNA cocktail consisting of Oct4, Sox2, Klf4, C-
Myc, Lin28, and nGFP was added days 1 to 3. On day 4, both the
miRNA and mRNA cocktails were added. On day 5 to day 11 of mRNA
reprogramming the ﬁbroblasts were treated with only the mRNA cock-
tail. Transfections were performed at the same time each day. Induced
pluripotent stem cell colonies emerging from the ﬁbroblast culture
were hand-picked and transferred to a 24well dishwithMEFs. Colonies
were then serially expanded. Sendai virus reprogramming was per-
formed as previously described (Fusaki et al., 2009). Human iPSC cul-
tures were routinely retained on MEFs (Globalstem) and cultured in
human ES media: KO-DMEM, 10% KO-SR, 1% NEAA, 1% glutamax, 0.1%
β-ME, 1% P/S, and 10 ng/mL bFGF. Media was supplemented with Y-
27632 upon passaging.MS-MLPA assay for gene copy number, andDNAmethylation of PWS region
genes
Genomic DNAwas isolated from PSC and PSC-derived neurons using
the Roche High Pure PCR Template Preparation Kit. gDNA was then an-
alyzed using the SALSA MLPA ME028 Prader Willi/Angelman probemix
(MRC-Holland) for copy number and DNAmethylation of PWS interval
genes.Neuronal differentiation
Induced pluripotent stem cells were differentiated to neurons using
amodiﬁed dual smadprotocol (Chambers et al., 2009). Undifferentiated
iPSCs cultured on MEFs were dissociated and re-plated onto freshMEFs
at a density of 200,000 cells/well of a 6-well plate in human ES media
with Y-27632 on day 0. On day 1, media was changed to EB media
(HES media without bFGF) supplemented with 10 μM SB431542 and
250 nM LDN193189 (LSB). Cells were treated with EB + LSB on days 2
and 3, 70% media changes were performed each day. On day 4, 75%
EB + 25% N2 (DMEM/F12 with 1× N2 supplement, 1% GlutaMAX, 1%
penicillin/streptomycin, 0.2 mM ascorbic acid, and 1.6% glucose) with
LSB was used. On day 5, 50% EB + 50% N2 with LSB was used. On day
6, 25% EB + 75% N2 with LSB was used. N2 supplemented with LSB
was used on days 7 to 10. On day 10, cells were dissociated and plated
onto poly-L-ornithine and laminin coated plates in N2 + LSB media
with Y-27632. 200,000 cells per well for a 6 well plate or 80,000 cells
per well for a 12 well plate were seeded. On day 11 the media was
changed to N2 plus B27without retinoic acid and 20 ng/uL recombinant
BDNF (R&D systems). Neuronswere harvested at D34 for RNA isolation.qRT-PCR for PWS region genes in iPSC
RNAwas isolated from PSC using the Qiagen RNeasy kit with DNAse
treatment. Total RNA was converted to cDNA using the Roche
Transcriptor First Strand cDNA Synthesis kit. qRT-PCR was performed
using Roche LightCycler 480 SYBRGreen IMastermix. Primers are listed
in Supplemental Table 2.
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iPSC lines of at least passage 10 were ﬁxed in 4% PFA for 10 min,
washed with PBS twice for 5 min, blocked for 1 h at room temperature
using 10% donkey serum, in PBS with 0.1% Triton X-100, washed with
PBS three times for 5min each, incubated in primary antibody overnight
at 4 °C, washed with PBS three times for 5 min, and incubated with sec-
ondary antibody at room temperature for 2 h. Primary antibodies and
dilutions used are as follows: Oct4 (1:500) (09-0023 Stemgent), Tra1-
60 (1:500) (MAB4360 Millipore), Tra1-81 (1:500) (MAB4381
Millipore), and Nanog (1:300) (Cell Signaling Technologies D73G4).
All Alexaﬂuor secondary antibodies were diluted 1:1000. Hoechst
33342 (Sigma)was used tomark nuclei. Imagingwas done on Olympus
IX71 epiﬂuorescence microscope with an Olympus DP30 monochrome
camera.Monochrome imageswere then assigned the ﬂuorophore color.
Nanostring N-Counter Pluripotency Gene Expression Assay in iPSC
iPSC were screened for endogenous expression of pluripotency
markers LIN28,NANOG,OCT4, SOX2, ZFP42, endogenous expression of ﬁ-
broblast marker KLF4, and exogenous expression of retroviral
transgenes using the Nanostring N-Counter Gene Expression Assay.
RNA was isolated from iPSC using the Qiagen RNeasy Plus kit. 100 ng
total input RNA was used; the Pluri25 custom code set was used for
the Nanostring N-Counter system.
Pluripotency analysis by Teratoma formation
Undifferentiated iPSCs (~250 K) were dissociated with TRP-LE and
pelleted by centrifuging at 0.8 RCF for 4 min at room temperature, the
pellet was re-suspended in 50 μL human ES media supplemented with
Y-27632. Cells were mixed 1:1 (vol:vol) in matrigel (Corning) and
were injected subcutaneously into the dorsalﬂank of NSG immunocom-
promised mice. Cells were allowed to grow for ~12 weeks; mice were
monitored twiceweekly for the appearance of growths and signs of dis-
tress.Micewere sacriﬁced and teratomaswere removed and ﬁxed over-
night in 70% ethanol then parafﬁn embedded, sectioned, and stained
with hematoxylin and eosin.
CGH SNP array
Deletion breakpoints in PWS microdeletion and PWS large deletion
iPSC were conﬁrmed by Comparative GenomeHybridization Single Nu-
cleotide Polymorphism Array using the Affymetrix Cytoscan SOMA kit.Genomic DNA was isolated from iPSC using the Roche High Pure PCR
Template Preparation Kit.
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